GSK Fluarix submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline anticipates an expedited review for its influenza vaccine Fluarix; the company submitted a BLA May 25. GSK has begun a manufacturing ramp-up aimed at providing 10 mil. doses of the vaccine for the 2005-06 flu season. Competitor Chiron, whose Fluvirin was removed from the market last season due to manufacturing issues, expects to begin shipping 25 mil. to 30 mil. doses of its product in the third quarter; the firm said FDA is slated to inspect its manufacturing facility in mid-June to late July...
You may also be interested in...
Chiron lowers Fluvirin production estimate
Chiron will produce 18 mil. to 20 mil. doses of its influenza vaccine Fluvirin for the 2005-06 flu season, the company says June 15. The firm previously projected its production level would be 25 mil. to 30 mil. doses (1Pharmaceutical Approvals Monthly June 2005, In Brief). Chiron expects FDA to inspect its manufacturing facility this month to determine whether deficiencies noted in a December 2004 warning letter have been resolved. GlaxoSmithKline plans to provide 10 mil. doses of its flu vaccine Fluarix for the 2005-06 season; the firm submitted the Fluarix BLA May 25...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip